Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
As of close of business last night, Corvus Pharmaceuticals Inc’s stock clocked out at $7.49, down -1.96% from its previous closing price of $7.64. In other words, the price has decreased by -$1.96 from its previous closing price. On the day, 5.55 million shares were traded. CRVS stock price reached its highest trading level at $7.955 during the session, while it also had its lowest trading level at $7.46.
Ratios:
To gain a deeper understanding of CRVS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.29 and its Current Ratio is at 8.29. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In the most recent recommendation for this company, Barclays on October 13, 2025, initiated with a Overweight rating and assigned the stock a target price of $16. On January 02, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $11. On August 18, 2023, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $7.Oppenheimer initiated its Outperform rating on August 18, 2023, with a $7 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 27 ’25 when ORBIMED ADVISORS LLC sold 1,176,332 shares for $4.16 per share. The transaction valued at 4,891,894 led to the insider holds 7,165,006 shares of the business.
Thompson Peter A. sold 1,176,332 shares of CRVS for $4,891,894 on Jun 27 ’25. The Director now owns 7,165,006 shares after completing the transaction at $4.16 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRVS now has a Market Capitalization of 559367232 and an Enterprise Value of 494689216.
Stock Price History:
The Beta on a monthly basis for CRVS is 0.71, which has changed by 0.6461538 over the last 52 weeks, in comparison to a change of 0.14402747 over the same period for the S&P500. Over the past 52 weeks, CRVS has reached a high of $9.60, while it has fallen to a 52-week low of $2.54. The 50-Day Moving Average of the stock is -6.87%, while the 200-Day Moving Average is calculated to be 39.28%.
Shares Statistics:
It appears that CRVS traded 1.14M shares on average per day over the past three months and 2227180 shares per day over the past ten days. A total of 74.68M shares are outstanding, with a floating share count of 57.33M. Insiders hold about 23.24% of the company’s shares, while institutions hold 37.72% stake in the company. Shares short for CRVS as of 1764288000 were 9812924 with a Short Ratio of 8.61, compared to 1761868800 on 9028415. Therefore, it implies a Short% of Shares Outstanding of 9812924 and a Short% of Float of 16.620001000000002.
Earnings Estimates
. The current market rating for Corvus Pharmaceuticals Inc (CRVS) reflects the collective analysis of 4.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.13 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.15 and -$0.16 for the fiscal current year, implying an average EPS of -$0.16. EPS for the following year is -$0.58, with 4.0 analysts recommending between -$0.53 and -$0.63.
